Kenneth Bloom named president at Human Longevity

Alok Saboo In this week's Chutes and Ladders, Kenneth Bloom has been named president of Human Longevity and Kevin Herde has been selected to be CFO of Sorrento. Plus more hirings ...

UPDATED: A patient in Akashi’s suspended Duchenne MD trial dies

John Carroll A little more than a week after Cambridge, MA-based Akashi Therapeutics suspended its study of a new drug for Duchenne muscular dystrophy after a patient was sent to the ...

Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging

John Carroll Imagine a drug that could clear away "senescent" cells and make the life span allotted to you healthier, absent many of the myriad diseases that can accumulate ...

Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen

John Carroll Genentech has moved to the head of a small group of players in the anti-inflammatory arena, bagging rights to an antibody that scrambles the connection between IL-33 and ...

The top 10 (possible) blockbusters that (might) launch this year

John Carroll Can't get enough of sell-side estimates on the big new drugs in the late-stage pipeline? Then we have a treat for you today. FierceBiotech News

Kochenderfer: ‘I think the main focus of the CAR field will be autologous cells…’

John Carroll Yesterday there was a brief, digital dust-up on Twitter over an abstract circulating online on a CAR-T study undertaken from the NCI's James Kochenderfer, one of the ...

BMS’ Opdivo evens the score in melanoma with two new FDA green lights

Tracy Staton Thanks to an FDA decision over the weekend, Bristol-Myers Squibb's immunotherapy Opdivo has caught back up to Merck's Keytruda in melanoma. And it won a new combination ...

Shire gets back on track with once-rejected eye drug

Damian Garde Shire has resubmitted the once-rejected eye treatment lifitegrast for FDA approval, handing in new data the company hopes will get its self-described blockbuster drug onto ...

ArGEN-X pulls in €16M to push cancer, autoimmune programs to clinical POC

Nick Paul Taylor Federated Investors has bought an 8.6% stake in arGEN-X. The deal sees arGEN-X sell shares worth €16 million ($ 17.5 million) to the major U.S. asset manager, ...

GlaxoSmithKline scientists accused of stealing drug R&D secrets for China scheme

John Carroll Yu Xue had a hard-earned reputation as a top chemist while she was working for GlaxoSmithKline in its Upper Merion, PA, facility. But Yu Xue–better known as Joyce–was ...

Surrounded by top scientists, Biden hustles up support for accelerated cancer R&D

John Carroll Vice President Joe Biden used the spotlight at the World Economic Forum in Davos to gather together some of the top players in drug R&D and highlight his push to speed ...

Video: Experts predict the future of Big Data at #JPM16

Alok Saboo FierceBiotech News
Page 1 of 11812345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS